CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance.
STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤微环境中CD8⁺ T细胞的丰度是免疫治疗疗效的关键决定因素。本研究表明,缺乏STING或TOX的CD8⁺ T细胞表现出显著增强的抗肿瘤活性,伴有肿瘤浸润增强以及IFN-γ和颗粒酶B产生增加。这些STING或TOX缺陷细胞呈现干细胞样转录状态,并通过抑制脂质过氧化通路同时促进线粒体生物发生来抵抗铁死亡。在机制上,STING和TOX形成正调控环路,抑制HO-1表达,导致肿瘤浸润CD8⁺ T细胞中铁蓄积、线粒体氧化应激和铁死亡。我们进一步鉴定乳酸为微环境触发STING-TOX-HO-1介导的CD8⁺ T细胞铁死亡的因子。在小鼠肿瘤模型中,工程化的STING/TOX缺陷CD8⁺ T细胞与免疫检查点阻断、化疗或STING激动剂协同增强肿瘤控制。这些发现揭示了调控肿瘤中CD8⁺ T细胞铁死亡的核心通路,并提出了克服免疫治疗耐药的治疗策略。
CD8 + T cell abundance within the tumor microenvironment is a critical determinant of immunotherapy efficacy.
Here we show that CD8⁺ T cells lacking STING or TOX display markedly improved antitumor activity, with enhanced tumor infiltration and elevated IFN-γ and granzyme B production. These STING or TOX deficient cells exhibit a stem-like transcriptional state and resist ferroptosis by suppressing lipid peroxidation pathways while promoting mitochondrial biogenesis.
Mechanistically, STING and TOX form a positive regulatory loop that represses HO-1 expression, leading to iron accumulation, mitochondrial oxidative stress, and ferroptosis in tumor-infiltrating CD8⁺ T cells.
We further identify lactate as a microenvironmental trigger of STING-TOX-HO-1-mediated CD8 + T-cell ferroptosis. In mouse tumor models, engineered STING/TOX-deficient CD8⁺ T cells synergize with immune checkpoint blockade, chemotherapy, or STING agonist to enhance tumor control.
These findings reveal a central pathway governing CD8⁺ T-cell ferroptosis in tumors and suggest therapeutic strategies to overcome immunotherapy resistance.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。